Form 4 for LLY Lilly (Eli)
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-10 · accession 0000059478-25-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-12 | 2025-02-10 | LLY | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | S - Sale | $863.21 | -5,000 | 118.6K | -4% | -$4.32M |
| D | 2025-02-12 | 2025-02-10 | LLY | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | A - Grant | $868.88 | +18.8K | 136.7K | +16% | +$16.31M |
| D | 2025-02-12 | 2025-02-10 | LLY | Skovronsky Daniel | EVP, CSO, Pres. LRL, LLY Imm | A - Grant | $0.00 | +12.7K | 12.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | S | D | 3,950 | $862.69 | 118,938.36 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 2 | Common | Common Stock | 2025-02-10 | A | A | 18,771.75 | $868.88 | 136,660.11 | D | — | — | |
| 3 | Common | Common Stock | 2025-02-10 | S | D | 710 | $865.76 | 117,888.36 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 4 | Common | Common Stock | 2025-02-10 | S | D | 340 | $863.97 | 118,598.36 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 5 | Derivative | Restricted Stock Unit | 2025-02-10 | A | A | 12,684 | $0.00 | 12,684 | D | — · 2026-02-01 to 2026-02-01 | 12,684 Common Stock | (F4) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |